Professor Alan Brennan BSc (London), MSc (London), PhD (Sheffield)

Alan Brennan

Director of Health Economics and Decision Science; Professor of Health Economics and Decision Modelling

Address:
HEDS, ScHARR
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield S1 4DA
Tel: (+44) (0)114 222 0684
Fax: (+44) (0)114 272 4095
Room 1023

email : a.brennan@sheffield.ac.uk

About Alan

Alan studied for BsC Mathematics at Imperial College London and then MSC Operational Research at the London School of Economics before joining the NHS to work in and then lead the Trent Operational Research Unit. Since moving the OR team into Sheffield University in 1994, Alan has been developing and applying modelling in support of healthcare decision-making nationally and internationally across a large range of diseases, interventions, service planning and policy issues.

Research interests

  • Use of modelling and data analysis to assess broader interventions.
  • Assessing cost-effectiveness of new treatments for NICE.
  • Bayesian methods in cost-effectiveness analysis to inform future research priorities.
  • Value of information and Bayesian methods to inform research priorities.
  • Cost effectiveness modelling methods.
  • Rheumatoid Arthritis.
  • Diabetes, Obesity, CHD Modelling.
  • Pharmaco-economics
    - Alzheimers
    - Renal Disease
  • Health Systems Modelling
    - Cervical Screening
    - Ambulance Services
    - Re-engineering

Activities and Distinctions

Methodological developments include Bayesian methods in cost effectiveness analysis to inform future research priorities.

PHD Supervision

Alan is currently supervising PhD students in the area of Mathematical Modelling Methods for Cost Effectiveness Analysis of Health Care Interventions and Health Care Systems. If you are interested in applying to study for a PhD under Alan's supervision please contact Charlotte Hollins at scharrtu@sheffield.ac.uk.

http://www.shef.ac.uk/scharr/prospective_students/researchdegrees

Alan has also been funded to undertake PhD supervision of a MRC PhD studentship on Bayesian Clinical trial simulation in the area of breast cancer and is seeking a student to start in Sept/Oct 2009.

http://www.shef.ac.uk/scharr/prospective_students/researchdegrees/studentships.html

Grants

Novartis Modelling cost effectiveness of Exelon Patch. September 2006 – July 2007. £121,415

Astra Zeneca Rheumatoid Arthritis drug development model project. September 2006. £16,740

Shire Pharmaceuticals Develop the Fosrenol pharmacoeconomic model: Incorporating calcium and phosphate mortality evidence from Block 2004 and preparing economic evaluation for submission to Australian regulatory authorities. June 2006. £85,000

Novartis Modelling the cost effectiveness of Vildagliptin for the treatment of type 2 Diabetes (Phase 1). September 2006 – October 2006. £38,400 and (Phase 2). January 2007 – March 2007. £73,750

NHS Cancer Screening Programme Option appraisal: screening for bowel cancer Bayesian synthesis modelling. September 2004 – April 2005 £24,200

Wellcome Trust To examine the cost effectiveness of different forms of organisation of diagnostic services for patients with TIA using computer modelling. April 2002 – April 2003. £80,000

Collaborations

  • Anthony O’Hagan and Jeremy Oakley, Probability & Statistics, University of Sheffield, Samer Kharroubi Value of Information, University of York.
  • Jonathan Michaels HTA in Vascular and Stroke Related Diseases, University of Sheffield.
  • Deborah Symmons, ARC Epidemiology Unit, University of Manchester, BSRBR (British Society for Rheumatology Biologics Register).
  • Frederick Wolfe, University of Kansas and Kaleb Michaud Standford University, Cost Effectiveness of Rheumatoid Arthritis treatments in the US.Nick Bansback, University of British Columbia and Richard Nixon MRC University of Cambridge, Cost Effectiveness of Rheumatoid Arthritis treatments in the UK.
  • Stephen Chick, INSEAD France and Ruth Davies, University of Warwick, Simulation Modelling in Healthcare.
  • Karl Claxton and Mark Sculpher, University of York and Keith Abrams University of Leicester, Health Economic Modelling for NICE decision support unit.

Key Publications since 2001

  • Brennan A, Kharroubi S, O'Hagan A and Chilcott J. Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms. Medical Decision Making 2007, 27: 448-470
  • Brennan A and Kharroubi S. Expected Value of Sample Information for Weibull Survival Data. (accepted in Health Economics)
  • Brennan A Chick SE, and Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Economics 2006, 15: 1295-1310.
  • Brennan A and Kharroubi S. Efficient computation of partial expected value of sample information using Bayesian approximation. Journal of Health Economics 2007, 26: 122-148.
  • Warren E, Brennan A, and Akehurst R. Cost effectiveness of sibutramine in the treatment of obesity. Medical Decision Making 2004, 24: 9-19.
  • Brennan A, Bansback N, Reynolds A and Conway P. Modelling the cost effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004, 43: 62-72.

Link to the HEDS publications database

Section

Alan Brennan is based in Health Economics and Decision Science (HEDS)

Health Economics and Decision Science

Downloads


12 August 09